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Elevation of serum sphingosine-
1-phosphate attenuates impaired 
cardiac function in experimental 
sepsis
Sina M. Coldewey1,2, Elisa Benetti3, Massimo Collino3, Josef Pfeilschifter4, 
Christoph Sponholz1, Michael Bauer1,2, Andrea Huwiler5 & Christoph Thiemermann6
Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced in septic patients and 
are inversely associated with disease severity. We show that serum S1P is reduced in human sepsis and 
in murine models of sepsis. We then investigated whether pharmacological or genetic approaches that 
alter serum S1P may attenuate cardiac dysfunction and whether S1P signaling might serve as a novel 
theragnostic tool in sepsis. Mice were challenged with lipopolysaccharide and peptidoglycan (LPS/
PepG). LPS/PepG resulted in an impaired systolic contractility and reduced serum S1P. Administration 
of the immunomodulator FTY720 increased serum S1P, improved impaired systolic contractility 
and activated the phosphoinositide 3-kinase (PI3K)-pathway in the heart. Cardioprotective effects 
of FTY720 were abolished following administration of a S1P receptor 2 (S1P2) antagonist or a PI3K 
inhibitor. Sphingosine kinase-2 deficient mice had higher endogenous S1P levels and the LPS/
PepG-induced impaired systolic contractility was attenuated in comparison with wild-type mice. 
Cardioprotective effects of FTY720 were confirmed in polymicrobial sepsis. We show here for the first 
time that the impaired left ventricular systolic contractility in experimental sepsis is attenuated by 
FTY720. Mechanistically, our results indicate that activation of S1P2 by increased serum S1P and the 
subsequent activation of the PI3K-Akt survival pathway significantly contributes to the observed 
cardioprotective effect of FTY720.
In sepsis life-threatening organ dysfunction occurs due to a dysregulated host response to infection1. Among the 
various organ systems that fail in sepsis, the cardiovascular system plays a prominent role. The development of left 
ventricular systolic dysfunction is common in patients with severe sepsis and is associated with increased mortal-
ity2,3. However, the pathophysiology of septic cardiomyopathy is not well understood4, but may be a consequence 
of dysregulated systemic inflammation.
Bioactive lipids are increasingly recognized as key mediators determining progression and resolu-
tion of inflammation5,6. One molecule that has been attributed a key role in inflammation is the lipid 
sphingosine-1-phosphate (S1P). This biologically active phospholipid mediator acts as a ligand of five different 
high affinity S1P receptors, denoted S1P1-57, which belong to the superfamily of G protein-coupled receptors 
(GPCR) and couple to a variety of signal transduction cascades either through Gi, Gq, G12/13 or small G proteins8. 
This diversity of S1P receptor-triggered signal transduction implicates a multitude of physiological and patho-
physiological functions of extracellular S1P including the promotion of cell growth and survival, cell migration, 
but also the enhancement of endothelial barrier function9–12. Consequently, targeting of S1P signaling by the 
development of specific pharmacological tools may have therapeutic potential in diseases associated with dys-
function of endothelial barrier13–16, such as sepsis.
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Most notably, it has been reported recently that S1P serum levels are decreased in patients with sepsis and 
are inversely associated with disease severity17. However, it remains unclear if this observation is associative or 
whether there is a true cause-effect relationship between S1P levels and cardiac (dys)function. Thus, S1P (and/or 
its signaling pathway) may serve as a biomarker or even as a theragnostic target in patients with sepsis.
We show that serum S1P is reduced in human and experimental murine sepsis. We then aimed to elucidate the 
role of S1P and its therapeutic potential in ameliorating sepsis-induced cardiomyopathy in a reverse-translational 
approach. To address our objectives, we employed two different murine models of experimental sepsis comple-
menting each other by recapitulating some individual features of the human disease. Mice received either cell 
wall fragments from Gram-negative (lipopolysaccharide, LPS) and Gram-positive (peptidoglycan, PepG) bacteria 
to induce severe multiple organ dysfunction (MOD) including impaired systolic contractility of the heart (for 
mechanistic studies) or they underwent cecal-ligation and puncture (CLP) to induce septic cardiomyopathy (for 
proof of principle studies). Specifically, we investigated the effects and underlying mechanisms of pharmacolog-
ical (administration of the immunomodulator FTY720) or genetic (sphingosine kinase-2 deficient (SPHK-2−/−) 
mice) approaches to alter S1P receptor signaling on the impaired systolic contractility and S1P levels in experi-
mental sepsis.
Methods
Additional details relating to materials and methodology are provided in the online data supplement.
Use of human subjects–ethic statement. The methods using human subjects were carried out in 
accordance with the approved guidelines. Specifically, following approval of the local ethics committee of Jena 
University Hospital, Germany (application no 2160-11/07, 2712-12/09), written informed consent for blood sam-
pling, sample analysis and data collection was obtained from all patients or legal surrogates before enrolment.
Human pilot study. Human samples were collected from a large cohort of septic patients admitted to the 
multidisciplinary intensive care unit of Jena University Hospital18. Samples were snap frozen and stored at −80 °C 
in the certified biobank of the Center for Sepsis Control & Care at Jena University Hospital. All samples were 
prospectively collected within 24 h or 72 h (± 6 h) after the patients fulfilled criteria of severe sepsis/septic shock 
according to ACCP/SCCM matching the newly introduced criteria for sepsis/septic shock (in accordance to 
the sepsis-3)1. To enable best possible homogeneity, septic patients (n = 19) were selected based on fulfilling 
anastomosis insufficiency after major abdominal surgery as a well-defined focus of this study. We included 28-d 
survivors (n = 9) and non-survivors (n = 10). Further information on patients characteristics are displayed in 
Supplementary Table S1.
Control patients (n = 11) underwent minimal invasive direct coronary bypass surgery (n = 5) or cardiac sur-
gery with cardio-pulmonary bypass (n = 6). Serum samples of each patient were collected prior to operation 
(after cannulation) and early postoperative (suture), reflecting an age-matched cohort with signs of systemic 
inflammation.
Use of experimental animals–ethic statement. The experimental protocols using animals were car-
ried out in accordance with the approved guidelines and were approved by the Home Office, London, UK (pro-
ject licenses reference numbers: PPL 70/6525, PPL 70/7348; personal license number: PIL 70/22807). The local 
‘Animal Use and Care Committee’ approved animal experiments in accordance with the derivatives of both, the 
‘Home Office guidance on the Operation of Animals (Scientific Procedures) Act 1986’, and the ‘Guide for the Care 
and Use of Laboratory Animals’ of the National Research Council.
Model of multiple organ dysfunction caused by LPS/PepG co-administration. This study was car-
ried out on 2-month-old male C57BL/6J mice (Charles River, Kent, UK) or sphingosine kinase-2 deficient (SPHK-
2−/−, Genoway, Lyon, France) mice weighing 25–30 g, receiving a standard diet and water ad libitum. Infomation 
on generation of SPHK-2−/− mice can be found in the Supplementary. C57BL/6J wild-type or SPHK-2−/− mice 
received i.p.-injections of LPS (9 mg/kg)/PepG (1 mg/kg) or its vehicle (0.9% saline). Sham mice were not sub-
jected to LPS/PepG, but were otherwise treated in the same way. At 1 h after LPS/PepG challenge, mice were 
treated with FTY720 (0.1 mg/kg i.v.) or its vehicle (10% DMSO). To elucidate the role of different S1P receptors in 
the observed effects of FTY720, mice received (45 min after LPS/PepG and 15 min prior to FTY720) the selective 
phosphatidylinositol 3 (PI3)-kinase inhibitor LY294002 (0.3 mg/kg i.v.) or the selective S1P2 receptor antago-
nist JTE 013 (1 mg/kg i.v.) or (1 h after LPS/PepG) the selective S1P1 receptor agonist SEW2871 (1 mg/kg i.v.) 
or vehicle (10% DMSO).
Model of polymicrobial sepsis caused by cecal ligation and puncture (CLP). This study was car-
ried out on 8-month-old male C57BL/6J mice (Charles River, Kent, UK) weighing 35–45 g, receiving a standard 
diet and water ad libitum. C57BL/6J mice underwent CLP (18-G needle, double puncture) or sham operation. 
Ringer´s solution (1 ml/mouse s.c.) was administered after surgery. Mice received antibiotic (imipenem/cilastin; 
20 mg/kg i.p.) and analgesic (buprenorphine; 0.05 mg/kg s.c.) therapy as well as fluid resuscitation (Ringer´s solu-
tion; 0.5 ml/mouse s.c.) 6 and 18 h after surgery19,20. Sham mice were not subjected to CLP, but were otherwise 
treated the same way. At 1 h after CLP, mice were treated with FTY720 (0.1 mg/kg i.v.) or vehicle (10% DMSO).
Quantification of organ dysfunction/injury. Cardiac function was assessed in mice subjected to LPS/
PepG or CLP at 18 h or 24 h, respectively, via echocardiography using a Vevo-770 imaging system (Visual Sonics, 
Toronto, Canada)20,21. Then, the experiment was terminated and organ and blood samples were collected for 
quantification of organ dysfunction and injury.
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Quantification of S1P. Lipid extraction in serum samples was performed according to Bligh and Dyer22. 
S1P concentration was determined by liquid chromatography-coupled tandem mass spectrometry (LC/MS/MS) 
in a blinded fashion23.
Immunoblot analysis. Semi-quantitative immunoblot analyses were carried out in mouse heart tissues as 
described previously20.
Statistics. Values are presented as box and whisker (min to max) with mean or as mean ± standard error 
of the mean (SEM) of n observations, where n represents the number of patients/animals studied. Due to the 
relatively low n-numbers, data (assumed to be not normally distributed) was assessed by Kruskal-Wallis test and 
Dunn´s test (corrected for multiple comparisons) unless otherwise stated. A P-value of less than 0.05 was consid-
ered to be statistically significant.
Results
Additional results are provided in the online Supplementary.
S1P serum concentrations are decreased in patients with sepsis and in mice challenged 
with LPS/PepG. S1P serum levels are significantly lower in septic patients compared to control patients 
(P = 0.0006, control T1 vs. sepsis D1). This effect was independent of the chosen time point (day 1 or day 3 after 
sepsis diagnosis) of blood sampling (Fig. 1a). A subanalysis revealed lower S1P levels in 28-day non-survivors 
compared to survivors, however, this effect was not significant (Fig. 1b).
When compared to sham-operated mice, LPS/PepG challenge caused a significant (P = 0.0005) fall in serum 
S1P levels (Fig. 2a) as well as a significant (P < 0.0001) decline in percentage ejection fraction (EF) (Fig. 2b) and, 
hence, cardiac dysfunction.
Cardiac dysfunction following LPS/PepG co-administration is attenuated by FTY720 treatment. 
The immunomodulator FTY720 is a structural analogue of S1P and acts in its phosphorylated isoform as an 
unselective agonist on S1P1 and S1P3-5 and a selective functional antagonist on S1P124. There is evidence that 
FTY720, enhances serum S1P levels by inhibiting S1P lyase activity25. Thus, we investigated the effects of FTY720 
on both serum S1P levels and cardiac function in mice challenged with LPS/PepG. There were no significant 
differences in percentage EF, fractional shortening (FS) and fractional area change (FAC) in sham animals treated 
with FTY72026 or vehicle (Fig. 3a–d). When compared to the sham animals, mice subjected to LPS/PepG demon-
strated a significant reduction of percentage EF (P = 0.0001), FS (P < 0.0001) and FAC (P < 0.0001), indicating 
impaired systolic contractility in vivo (Fig. 3a–d). Delayed intravenous administration of FTY720 (0.1 mg/kg) 1 h 
after LPS/PepG challenge significantly attenuated this impaired systolic contractility, indicated by significantly 
higher values for EF (P = 0.0332), FS (P = 0.0378) and FAC (P < 0.0482) (Fig. 3a–d).
S1P serum level following LPS/PepG co-administration are increased by FTY720 treatment. 
Administration of FTY720 caused a significant rise in serum S1P levels in both sham-operated animals and ani-
mals challenged with LPS/PepG (P < 0.0001) (Fig. 3e). These data (Fig. 3) support the view that the increase in 
serum S1P afforded by FTY720 might contribute to an improvement in cardiac function.
Figure 1. Decreased S1P serum concentrations in patients with sepsis. (a,b) S1P serum levels were 
assessed by LC/MS/MS in control patients (undergoing cardiac surgery prior to operation (T1 n = 11) and 
early postoperative (T2 n = 11) and in patients with severe sepsis/septic shock at day 1 (D1 n = 19) and day 3 
(D3 n = 17) after diagnosis. (b) Septic patients were divided in 28-d survivors (D1 n = 9; D3 n = 9) and 28-d 
non-survivors (D1 n = 10; D3 n = 8). Data are expressed as box and whisker min to max for n number of 
observations. + = mean value. * P < 0.05 sepsis vs. control T1 #P < 0.05 sepsis vs. control T2 (Kruskall-Wallis 
test with Dunn´s multiple comparisons test).
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Figure 2. Effect of LPS/PepG on S1P serum levels and on cardiac function in C57BL/6J wild type mice. 
At 18 h after LPS/PepG or vehicle (sham) administration to 2-month-old male C57BL/6J wild type mice 
(a) S1P serum levels were assessed by LC/MS/MS, or (b) the percentage ejection fraction was assessed by 
echocardiography. The following groups were studied: sham + vehicle (n = 8); LPS/PepG + vehicle (n = 8). Data 
are expressed as means ± SEM, *** P = 0.005 vs. sham + vehicle, **** P = 0.0001 vs. sham + vehicle (unpaired 
t-test).
Figure 3. Effect of LPS/PepG co-administration and treatment with FTY720 on cardiac function and 
S1P serum levels in C57BL/6J wild type mice. (a) Representative M-mode echocardiograms and legend of 
all groups studied. (b) Percentage ejection fraction, (c) fractional shortening (d), fractional area change were 
assessed via echocardiography and (e) S1P serum levels were assessed by LC/MS/MS 18 h subsequent to vehicle 
administration (sham) or LPS/PepG co-administration in 2-month-old male C57BL/6J wild type mice. At 
1 h after LPS/PepG challenge mice were treated either with FTY720 (0.1 mg/kg) or vehicle (10% DMSO). The 
following groups were studied: C57BL/6J sham + vehicle (n = 8); C57BL/6J sham + FTY720 (n = 3); C57BL/6J 
LPS/PepG + vehicle (n = 14); C57BL/6J LPS/PepG + FTY720 (n = 15). Data are expressed as means ± SEM 
for n number of observations. *P < 0.05 vs. C57BL/6J LPS/PepG + vehicle (Kruskall-Wallis test with Dunn´s 
multiple comparisons test).
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Effect of LPS/PepG co-administration on cardiac function in SPHK-2 deficient mice. Serum 
S1P-levels are higher in sphingosine kinase 2 deficient (SPHK-2−/−) mice27–29. If serum S1P levels do indeed (as 
we propose) protect the heart against the cardiac dysfunction caused by LPS/PepG, then one would expect SPHK-
2−/− mice to be more resistant to the cardiac dysfunction caused by LPS/PepG.
When compared to SPHK-2−/− sham mice, SPHK-2−/− mice subjected to LPS/PepG developed a signifi-
cant reduction of percentage EF (P = 0.0059), FS (P = 0.0063) and FAC (P = 0.0148) and, thus, impaired systolic 
contractility (Fig. 4a–d). Most notably, systolic contractility was significantly less impaired in SPHK-2−/− mice 
than in wild-type mice (Figs 3a–d and 4a–d) subjected to LPS/PepG co-administration (Mann Whitney test 
EF C57BL/6J LPS/PepG vs. Sphk2−/− LPS/PepG, (P = 0.0422)), indicating a protective effect mediated by 
SPHK-2 deficiency. Serum S1P-levels were higher in sham-operated SPHK-2−/− mice (3.099 ± 0.4644) than in 
sham-operated wild-type mice (2.334 ± 0.1644) (Figs 4e and 3e). While LPS/PepG challenge in wild-type mice 
(and sepsis in patients) resulted in a significant decline in serum S1P levels, this was not observed in SPHK-2−/− 
mice challenged with LPS/PepG (P > 0.999) (Fig. 4e). This supports the view that higher S1P levels are associated 
with a better cardiac function. Consequently, delayed intravenous administration of FTY720 (0.1 mg/kg) 1 h after 
LPS/PepG challenge in SPHK2−/− mice did not significantly attenuate percentage EF, FS and FAC and serum S1P 
(Fig. 4a–e).
Effect of LPS/PepG co-administration and treatment with FTY720 on Akt, eNOS and ERK1/2 
phosphorylation in murine heart tissue. Activation of S1P receptors results in activation (phosphoryl-
ation) of Akt, eNOS and ERK1/230, while activation of Akt and eNOS improves cardiac function in mice with 
sepsis31 and activation of ERK1/2 mediates cardioprotection32. Thus, we investigated the effects of FTY720 on 
the degree of phosphorylation of Akt on Ser473 (Fig. 5a), eNOS on Ser1177 (Fig. 5b) and ERK1/2 on Thr202/Tyr204 
and Thr185/Tyr187 (Fig. 5c), respectively. FTY720 did not affect the degree of phosphorylation of any of the above 
proteins in sham-operated animals. In contrast, FTY720 significantly increased phosphorylation of Akt on Ser473 
Figure 4. Effect of LPS/PepG co-administration and treatment with FTY720 on cardiac function and S1P 
serum levels in sphingosine kinase-2 deficient mice. (a) Representative M-mode echocardiograms and legend 
of all groups studied. (b) Percentage ejection fraction, (c) fractional shortening (d), fractional area change were 
assessed via echocardiography and (e) S1P serum levels were assessed by LC/MS/MS 18 h subsequent to vehicle 
administration (sham) or LPS/PepG co-administration in 2-month-old male SPHK-2−/− mice. At 1 h after 
LPS/PepG challenge mice were treated either with FTY720 (0.1 mg/kg) or vehicle (10% DMSO). The following 
groups were studied: SPHK-2−/− sham + vehicle (n = 6); SPHK-2−/− sham + FTY720 (n = 6), SPHK-2−/− LPS/
PepG + vehicle (n = 16), SPHK-2−/− LPS/PepG + FTY720 (n = 14). Data are expressed as means ± SEM for 
n number of observations. * P < 0.05 vs. SPHK-2−/− LPS/PepG + vehicle (Kruskall-Wallis test with Dunn´s 
multiple comparisons test).
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(P = 0.0208) (Fig. 5a), eNOS on Ser1177 (P = 0.00273) (Fig. 5b) and ERK1/2 on Thr202/Tyr204 and Thr185/Tyr187 
(P = 0.00273) (Fig. 5c) in mice challenged with LPS/PepG.
Role of S1P1 and S1P2 on the FTY720 mediated effects on cardiac function in LPS/PepG challenged 
mice. Activation of the S1P receptors S1P1, S1P2 or S1P3 results in activation of the PI3K/Akt/eNOS pathway 
(Fig. 6a). The beneficial effects of FTY720 on cardiac dysfunction in LPS/PepG challenged mice was abolished in 
mice that received either the selective phosphatidylinositol 3 (PI3)-kinase inhibitor LY29400233 or the selective 
S1P2 antagonist JTE01334 15 min prior to FTY720 treatment (Fig. 6b,c). Of note, one mouse of the JTE013 treated 
group died. Administration of the selective S1P1 agonist SEW287135 (1 mg/kg i.v.) (Fig. 6b,c) or 10 mg/kg (data 
not shown) at 1 h after LPS/PepG challenge did not significantly attenuate percentage EF, FS and FAC in LPS/
PepG challenged mice. These results suggest that activation of S1P2 by S1P plays an important role in mediating 
the cardioprotective effects of FTY720 via down-stream PI3K signaling.
Cardiac dysfunction following polymicrobial sepsis is attenuated by FTY720 treatment. 
Having shown that FTY720 prevents the impairment in cardiac function caused by LPS/PepG, we wished to 
confirm these findings in a model of polymicrobial sepsis (CLP with fluid resuscitation and antibiotics) mimick-
ing the clinical syndrome (Fig. 7). We obtained no significant differences in percentage EF, FS and FAC in sham 
animals treated with FTY720 or vehicle. When compared to sham animals, mice that underwent CLP demon-
strated a significant reduction in percentage EF (P = 0.0002), FS (P = 0.0002) and FAC (P = 0.0002), indicating 
impaired systolic contractility (Fig. 7). Delayed intravenous administration of FTY720 (0.1 mg/kg) 1 h after CLP 
significantly attenuated this impaired systolic contractility, indicated by a significant increase of percentage EF 
(P = 0.0117), FS (P = 0.0205) and FAC (0.0031) (Fig. 7).
Figure 5. Effect of LPS/PepG co-administration and treatment with FTY720 on Akt, eNOS and ERK1/2 
phosphorylation in heart tissue of C57BL/6J wild type mice. At 1 h after administration of LPS/PepG or 
vehicle (sham), mice were treated with FTY720 (0.1 mg/kg) or vehicle (10% DMSO). Signaling events in heart 
tissue were assessed at 18 h. Each immunoblot is from a single experiment and is representative of three separate 
experiments. All values were corrected for the corresponding β -actin band. Densitometric analysis of the bands 
is expressed as relative optical density (OD) of (a) phosphorylated Akt (pSer473) corrected for the corresponding 
total Akt content (Σ Akt) and normalized using the related sham band; (b) phosphorylated eNOS (pSer1177) 
corrected for the corresponding total eNOS content (Σ eNOS) and normalized using the related sham band 
and; (c) phosphorylated ERK1 (pThr202/pTyr204) and ERK2 (pThr185/pTyr187) corrected for the corresponding 
total ERK1 or ERK2 content (Σ ERK1 or Σ ERK2) and normalized using the related sham band. Data are 
expressed as mean ± SEM for n number of observations. * P < 0.05 vs. LPS/PepG + vehicle (Kruskall-Wallis test 
with Dunn´s multiple comparisons test).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:27594 | DOI: 10.1038/srep27594
Effect of sepsis and treatment with FTY720 on Akt, eNOS and ERK1/2 phosphorylation in 
mouse heart tissue. Having shown that FTY720 activates Akt, eNOS and ERK1/2 in our model of MOD 
caused by LPS/PepG, we aimed to validate these findings in CLP-induced polymicrobial sepsis. When compared 
with heart tissues from sham mice treated with vehicle, heart tissues from sham mice treated with FTY720 and 
those from mice that underwent CLP and treated with vehicle demonstrated no significant alterations in the 
degree of phosphorylation of Akt on Ser473 (Fig. 8), eNOS on Ser1177 (Fig. 8) and ERK1/2 on Thr202/Tyr204 and 
Figure 6. Role of S1P1 and S1P2 on observed LPS/PepG- and FTY720-mediated effects on cardiac function 
in mice. (a) S1P receptors S1P1-3, and the activation of ERK and PI3K/Akt/eNOS through Gi coupled signaling 
pathways. S1P activates S1P receptors. The S1P mimetic FTY720 acts in its phosphorylated isoform as an 
unselective agonist on S1P1 and S1P3 and a selective functional antagonist on S1P1. S1P1 exclusively couples 
to Gi, while S1P2 and S1P3 couple to Gi, G12/13 and Gq. Coupling of S1P receptors to Gi leads to activation of 
the Ras/ERK pathway and the PI3K/Akt/eNOS pathway. SEW2871: S1P1 agonist. JTE 013: S1P2 antagonist. 
LY294002: PI3K inhibitor. S1P: sphingosine-1-phosphate. FTY720-P: phosphorylated FTY720. (b) Percentage 
ejection fraction was assessed via echocardiography 18 h subsequent to LPS/PepG co-administration in 
2-month-old male C57BL/6J mice. At 1 h after LPS/PepG challenge mice were treated either with vehicle (10% 
DMSO) (n = 14), FTY720 (0.1 mg/kg) (n = 15) or the selective S1P1 agonist SEW2871 (1 mg/kg i.v.) (n = 3). 
Or mice received (45 min after LPS/PepG and 15 min prior to FTY720) the selective PI3K inhibitor LY294002 
(0.3 mg/kg i.v.) (n = 6) or the selective S1P2 antagonist JTE 013 (1 mg/kg i.v.) (n = 6). One animal, which 
received JTE 013, died and was not included in the statistics. Data are expressed as means ± SEM for n number 
of observations. * P < 0.05 LPS/PepG + FTY720 vs. LPS/PepG + vehicle; #P < 0.05 vs. LPS/PepG + FTY720 
(Kruskall-Wallis test with Dunn´s multiple comparisons test). (c) Summary of the experimental setup for 
acquisition of data provided in panel b.
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Thr185/Tyr187 (Fig. 8), respectively. However, treatment of CLP challenged mice with FTY720 resulted in a signif-
icantly increased phosphorylation of Akt on Ser473 (P = 0.0232) (Fig. 8), eNOS on Ser1177 (P = 0.0092) (Fig. S3b) 
and ERK1/2 on Thr202/Tyr204 and Thr185/Tyr187 (P = 0.0100) (Fig. 8).
Discussion
This study reports that serum S1P levels are significantly reduced in patients with sepsis and in animals chal-
lenged with LPS/PepG (reverse translation), which might contribute to septic cardiomyopathy. The lowest levels 
of S1P were found in patients that died in the acute phase of sepsis, while 28-day survivors appeared to have 
higher levels of serum S1P. Thus, our findings confirm and extend recently published data by Winkler et al.17. 
These authors investigated serum S1P levels in a larger cohort of patients with sepsis and found that serum S1P 
was decreased in sepsis and S1P levels negatively correlate with disease severity assessed by sofa score and 28-day 
mortality, however, their clinical study did not address the role of S1P in the pathophysiology of sepsis.
In mice, low levels of serum S1P were associated with a significant impairment in cardiac systolic contractil-
ity, and both pharmacological (FTY720) and genetic approaches (sphingosine kinase 2 deficiency) that increase 
serum S1P levels attenuated the cardiac dysfunction caused by LPS/PepG. These findings support our hypothesis 
that approaches, which enhance S1P serum levels, may reduce cardiac dysfunction and improve outcome in 
patients/animals with sepsis.
What, then, is the mechanism(s) by which high serum levels of S1P preserve cardiac function in sepsis? The 
S1P receptors S1P1, S1P2 and S1P3 activate the Akt survival pathway30 (Fig. 6a). When phosphorylated by it’s 
upstream regulator PI3K, Akt modulates inflammation, cell survival and growth36. Most notably, activation 
(resulting in phosphorylation of Ser473) of Akt attenuates the cardiac dysfunction caused by sepsis in mice20,21,31. 
Here, we show that the cardioprotective effects of FTY720 in sepsis are associated with increases in a) the serum 
levels of S1P and b) the phosphorylation of Ser473 on Akt resulting in the activation of the Akt survival pathway 
in the heart.
There is very good evidence that the activation of Akt results in the phosphorylation of eNOS (on Ser1177) and, 
hence, activation of eNOS37. Indeed, activation of S1P1, S1P2 and S1P3 activate the Akt/eNOS pathway. Activation 
of eNOS inhibits neutrophil adhesion, maintains microvascular patency38 and reduces the cardiac dysfunction 
in sepsis20,21,31. We have discovered that prevention of the cardiac dysfunction in sepsis afforded by FTY720 is 
associated with an increase in phosphorylation (on Ser1177) of eNOS. Thus, activation by FTY720/S1P of the Akt/
eNOS survival pathway may contribute to the beneficial effects of FTY720/S1P in mice with sepsis. Activation of 
the S1P receptors S1P1, S1P2 and S1P3 also activates the ERK1/2 pathway30 (Fig. 6a). Activation of ERK1/2 pro-
motes cell survival and proliferation30. Here we demonstrate that the cardioprotective effects afforded by FTY720 
are associated with an increase in the phosphorylation (on Thr202/Tyr204 and Thr185/Tyr187) of ERK1/2 resulting in 
the activation of these kinases.
Figure 7. Effect of cecal ligation and puncture and treatment with FTY720 on cardiac function in C57BL/6J 
wild type mice. (a) Representative M-mode echocardiograms and legend of all groups studied. (b) Percentage 
ejection fraction, (c) fractional shortening (d), fractional area change were assessed via echocardiography 24 h 
subsequent to CLP or sham-operation in 8-month-old male C57BL/6J wild type mice. The following groups 
were studied: sham + vehicle (n = 8); sham + FTY720 (n = 3), CLP + vehicle (n = 8), CLP + FTY720 (n = 10). 
Data are expressed as means ± SEM for n number of observations. * P < 0.05 vs. CLP + vehicle (Man Whitney 
test, two-tailed).
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One could argue that the cardioprotection afforded by FTY720 is independent of a rise in serum S1P levels. 
To address this important question we have used a molecular approach to maintain elevated S1P levels in sepsis: 
Mice with a functional deletion of sphingosine kinase 2 have been reported to have higher endogenous S1P serum 
levels27–29. We show here that SPHK-2−/− mice in comparison to wild type mice have a) elevated S1P serum levels 
b) exhibit no fall in S1P serum levels when challenged with LPS/PepG, and c) have less impairment in cardiac 
function when challenged with LPS/PepG. These findings further support the view that higher serum levels of 
S1P are associated with preservation in cardiac function in sepsis.
The activation of Akt/eNOS by the S1P receptors S1P1, S1P2 and S1P3 is dependent on the prior activation of 
PI3K (Fig. 6a). We report here that inhibition of PI3K (with LY294002) prevents the cardioprotective effects of 
FTY720 in sepsis (Fig. 6b). Thus, activation of PI3K (presumably secondary to the activation of the S1P recep-
tor(s) by S1P) plays an essential role in the cardioprotective effects of FTY720/S1P.
We designed further experiments to gain a better understanding of the specific S1P receptor(s) that mediate 
the cardioprotective effects of FTY720. SEW2871 is a selective and specific agonist of S1P135. SEW2871 did not 
significantly attenuate the cardiac dysfunction caused by LPS/PepG and, hence, did not mimic the effects of 
FTY720 in sepsis (Fig. 6b). Thus, it is less likely that the observed cardioprotective effects of FTY720 are second-
ary to the activation by S1P (or FTY720 itself) of the S1P1. In contrast, the S1P2 antagonist JTE 01334 abolished the 
cardioprotective effects of FTY720 indicating that these effects are (at least in part) secondary to the activation 
of S1P2 by S1P/FTY720 (Fig. 6b). It is possible that the activation of S1P3 also contributes to the cardioprotec-
tive effects of FTY720, as a) this receptor results in the activation of PI3K, and b) prevention of the activation 
of PI3K with LY294002 abolished the cardioprotective effects of FTY720. Thus, we provide evidence to suggest 
that the preserved cardiac function afforded by FTY720 in sepsis is at least in part secondary to the activation 
(by S1P) of S1P2 (and possibly S1P3). Interestingly, S1P activates Akt in cardiomyocytes and reduces the injury 
caused by myocardial ischemia-reperfusion, and both effects are lost in S1P2 and S1P3 double knock out mice39. 
Mechanistically, S1P2 and S1P3 are coupled to Ras homolog gene family member A (RhoA) activation40,41. RhoA 
Figure 8. Effect of cecal ligation and puncture (CLP) and treatment with FTY720 on Akt, eNOS and 
ERK1/2 phosphorylation in murine heart tissue. At 1 h after CLP or sham operation, mice were treated with 
either FTY720 (0.1 mg/kg) or vehicle. Signaling events in heart tissue were assessed at 24 h. Each immunoblot is 
from a single experiment and is representative of three separate experiments. All values were corrected for the 
corresponding β -actin band. Densitometric analysis of the bands is expressed as relative optical density (OD) 
of (a) phosphorylated Akt (pSer473) corrected for the corresponding total Akt content (Σ Akt) and normalized 
using the related sham band; (b) phosphorylated eNOS (pSer1177) corrected for the corresponding total eNOS 
content (Σ eNOS) and normalized using the related sham band and; (c) phosphorylated ERK1 (pThr202/pTyr204) 
and ERK2 (pThr185/pTyr187) corrected for the corresponding total ERK1 or ERK2 content (Σ ERK1 or Σ ERK2) 
and normalized using the related sham band. Data are expressed as mean ± SEM for n number of observations. 
* P < 0.05 vs. CLP + vehicle (Kruskall-Wallis test with Dunn´s multiple comparisons test).
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activation protects cardiomyocytes against ischemia/reperfusion injury42,43. In addition, cardiomyocyte apoptosis 
is reduced in vitro by activation of the RhoA/Rho-associated protein kinase/Focal adhesion kinase/PI3K/Akt 
signaling pathway44. Furthermore, S1P can also mediate cardiomyocyte survival via activation of the RhoA sign-
aling pathway involving RhoA, phospholipase C-ε and protein kinase D142. Importantly, it should be noted that 
FTY720 lacks affinity for S1P245, again supporting our view that the cardioprotective effects of FTY720 reported 
here are secondary to an increase in serum S1P levels after FTY720 treatment.
FTY720 is currently being used in the therapy of patients with multiple sclerosis46. Thus, it is, in principle, 
possible to evaluate the effects of FTY720 in patients with sepsis. Although systemic administration of TLR/
NOD-ligands, such as LPS or PepG, can produce many of the features of sepsis including cardiac dysfunction47, 
CLP-sepsis is the model of choice when testing the efficacy of new therapeutics in sepsis. We show here that the 
delayed administration (after onset of CLP) of FTY720 in a clinically relevant, murine model of sepsis (CLP) with 
fluid resuscitation and antibiotic therapy attenuates the cardiac dysfunction caused by sepsis (Fig. 7). Interestingly, 
preservation of cardiac function in sepsis by FTY720 was associated with activation of the Akt/eNOS and ERK1/2 
pathways (Fig. 8). These findings support the view that FTY720 attenuated the cardiac dysfunction in CLP-sepsis 
also in an Akt/eNOS and ERK1/2-dependent manner. FTY720 or S1P reduces the microvascular permeability in 
lung and kidney in mice challenged with LPS16 and FTY720 reduces plasma extravasation in rats with sepsis48. 
With this in mind, we have also investigated the effects of FTY720 on the renal dysfunction and liver injury asso-
ciated with LPS/PepG. Although less pronounced, we observed a trend towards protection by FTY720, which 
failed to reach significance (see Supplementary Table S2). Thus, it seems likely that the acute beneficial effect of 
S1P elevation is restricted to the cardiovascular system.
What, then, is known about the role of endogenous S1P in patients with sepsis? Under normal conditions, the 
main portion of blood S1P is bound to HDL (60%) and serum albumin (35%) and only a minor amount is avail-
able as free S1P49. In sepsis, HDL levels are reduced50 and the application of HDL reduced mortality in various 
animal models of sepsis and multiple organ dysfunction51–54. The mechanism(s) underlying the protective effect 
of HDL are not completely understood, but may be due to direct binding and trapping of endotoxins by HDL55,56, 
the down-regulation of pro-inflammatory adhesion molecules and of chemotactic factors51. Additionally, and 
especially in view of our data here, the protective effects of HDL may be mediated by HDL-associated S1P. 
Interestingly, the many of the beneficial effects of HDL including the cardioprotective effects may be mediated by 
S1P (reviewed in57). It was recently discovered that apoM is the direct carrier of S1P in HDL58. Remarkably, apoM 
also decreases in sepsis59 supporting the view that the apoM-S1P-HDL may play a role in sepsis. Whether the 
reduction of apoM transcription in the septic liver59 is causal to the reduced serum S1P in sepsis remains open.
In conclusion, we confirmed patients with severe sepsis have lower serum levels of S1P and report here for 
the first time that in mice pharmacological (FTY720) and genetic (SPHK2 deficiency) approaches to enhance 
S1P serum levels reduce the cardiac dysfunction caused by LPS/PepG. In a model of polymicrobial sepsis we 
provide proof-of-concept for a potential therapeutic application of strategies to increase S1P. Preservation of car-
diac function in sepsis by FTY720 is at least in part secondary to the activation (by S1P) of the S1P2 (and possibly 
S1P3) resulting in the PI3K-dependent activation of the Akt/eNOS and ERK1/2 pathways, which are known to be 
cardioprotective in animal models of sepsis. We speculate that FTY720 may be useful to elevate levels of S1P in 
patients with sepsis, which, in turn, may improve outcome in these patients. As FTY720 is used in patients with 
multiple sclerosis, it is, in principle, possible to evaluate the effects of this drug in patients with sepsis, although 
the known immunosuppressive effects of FTY720 need to be considered.
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